6-Bromo-4-(4-ethylpiperazin-1-yl)quinazoline | 307538-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-Bromo-4-(4-ethylpiperazin-1-yl)quinazoline
• CAS: 307538-58-5
• 化学式: C₁₄H₁₇BrN₄
• 分子量: 321.22
• InChiKey: QRIYSXNSZBAVNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-乙基哌嗪 、 6-溴-4-氯喹唑啉 在 吡啶 作用下， 以 乙醇 为溶剂， 生成 6-Bromo-4-(4-ethylpiperazin-1-yl)quinazoline
  参考文献：
  名称：

  Potent inhibitors of Huntingtin protein aggregation in a cell-based assay

  摘要：

  A quinazoline that decreases polyglutamine aggregate burden in a cell-based assay was identified from a high-throughput screen of a chemical-compound library, provided by the NIH Molecular Libraries Small Molecule Repository (MLSMR). A structure and activity study yielded leads with submicromolar potency. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.087

文献信息

• Identification of CDKI pathway inhibitors
  申请人：Chang Bey-Dih

  公开号：US20080033000A1

  公开（公告）日：2008-02-07

  The invention relates to the inhibition of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
• CDKI PATHWAY INHIBITORS AND USES THEREOF
  申请人：Chang Bey-Dih

  公开号：US20090281129A1

  公开（公告）日：2009-11-12

  The invention relates to the inhibition of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
• Potent inhibitors of Huntingtin protein aggregation in a cell-based assay
  作者：Alison Rinderspacher、Maria Laura Cremona、Yidong Liu、Shi-Xian Deng、Yuli Xie、Gangli Gong、Nathalie Aulner、Udo Többen、Katherine Myers、Caty Chung、Monique Andersen、Dušica Vidović、Stephan Schürer、Lars Brandén、Ai Yamamoto、Donald W. Landry

  DOI：10.1016/j.bmcl.2009.01.087

  日期：2009.3

  A quinazoline that decreases polyglutamine aggregate burden in a cell-based assay was identified from a high-throughput screen of a chemical-compound library, provided by the NIH Molecular Libraries Small Molecule Repository (MLSMR). A structure and activity study yielded leads with submicromolar potency. (C) 2009 Elsevier Ltd. All rights reserved.